C-Rad AB (publ)

Stockholm Stock Exchange CRAD-B.ST

C-Rad AB (publ) Debt to Equity Ratio for the year ending December 31, 2023: 0.01

C-Rad AB (publ) Debt to Equity Ratio is 0.01 for the year ending December 31, 2023, a -61.53% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.
  • C-Rad AB (publ) Debt to Equity Ratio for the year ending December 31, 2022 was 0.02, a -39.07% change year over year.
  • C-Rad AB (publ) Debt to Equity Ratio for the year ending December 31, 2021 was 0.03, a -25.89% change year over year.
  • C-Rad AB (publ) Debt to Equity Ratio for the year ending December 31, 2020 was 0.04, a -84.72% change year over year.
  • C-Rad AB (publ) Debt to Equity Ratio for the year ending December 31, 2019 was 0.24, a 0.00% change year over year.
Key data
Date Debt to Equity Ratio Debt to Income Ratio Debt to Tangible Net Worth Ratio Dividend Coverage Ratio
Market news
Loading...
Stockholm Stock Exchange: CRAD-B.ST

C-Rad AB (publ)

CEO Ms. Cecilia de Leeuw
IPO Date July 23, 2007
Location Sweden
Headquarters SjukhusvAegen 12K
Employees 98
Sector Health Care
Industries
Description

C-Rad AB (publ), together with its subsidiaries, develops, manufactures, and sells systems with applications in radiation therapy for the treatment of cancer worldwide. The company operates through two segments, Positioning and Imaging. Its products include Sentinel 4D CT, a laser-based optical surface scanning system; Catalyst, a 4D surface image guided radiation therapy (SIGRT) solution; Catalyst HD, an SIGRT solution on stereotactic radiation therapy for online patient tracking before and during treatment delivery; Catalyst+, an SIGRT solution for high precision patient positioning, intra-fraction motion management, and respiratory gating; and Catalyst+ HD, a solution for high precision patient positioning, intra-fraction motion management, and respiratory gating for conventional and stereotactic treatment delivery. The company's products also comprise Catalyst Tomo, an enhanced positioning solution for tomotherapy; Catalyst PT, a real-time tracking solution for particle therapy; Cyrpa laser positioning products; cAccessory, which automates the registration and validation of treatment accessories; and cPatient that automates patient identity validation without the need for contact between patients and devices. In addition, it offers installation, application training, and aftersales services. C-Rad AB (publ) was founded in 2004 and is headquartered in Uppsala, Sweden.

Similar companies

BIOT.ST

Biotage AB (publ)

USD 11.98

-2.51%

RAY-B.ST

RaySearch Laboratories AB (publ)

USD 20.58

0.68%

BOUL.ST

Boule Diagnostics AB (publ)

USD 0.89

14.73%

BONEX.ST

Bonesupport Holding AB (publ)

USD 32.97

-0.61%

CEVI.ST

CellaVision AB (publ)

USD 18.76

3.89%

StockViz Staff

January 15, 2025

Any question? Send us an email